Performance in delivering Clinical Research at PHT Q3 14/15 study met the 70 day target study within 70 day target study not met 70 day target

Size: px
Start display at page:

Download "Performance in delivering Clinical Research at PHT Q3 14/15 study met the 70 day target study within 70 day target study not met 70 day target"

Transcription

1 Performance in delivering Clinical Research at PHT Q3 14/15 study met the 70 day target study within 70 day target study not met 70 day target Research Ethics Committee 14/ES/0004 ALA-BCC-CT008 - A randomized, observer blind, multinational phase III study to evaluate the safety and efficacy of BF-200 ALA (Ameluz?) in comparison to Metvix? in the treatment of non-aggressive basal cell carcinoma (BCC) with photodynamic therapy (PDT) Available 6 Available 01/10/2019 Open Total recruited at site = 12 14/LO/0091 An observational cross-sectional study to describe the patient profile and secondary care management pathways for with hidradenitis suppurativa (HS) in the UK Available 10 Available 31/12/2014 Open Total recruited at site = 13; Timeline extended from the original date in contract of 31/12/2014 to 31/03/ /W/0612 A multicentre, randomised, double-blind, parallel group, placebo-controlled, phase III efficacy and safety study of benralizumab (MEDI-563) added to high-dose inhaled corticosteroid plus long-acting B2- agnoist in with uncontrolled asthma (SIROCCO) Available 1 Available 19/12/2014 Open Total recruited at site = 7; Study extended by sponsor from 19/12/14 to 13/02/15 12/WS/0305 A Prospective Randomized Comparison of the Biofreedom? Biolimus A9? Drug Coated Stent Versus the Gazelle? Bare Metal Stent in Patients at High Risk for Bleeding Available 15 Available 22/04/2014 Total recruited at site = 15; Sponsor extended recruitment period from Feb to 22/04/2014

2 13/W/0464 A Placebo-Controlled, Multicenter, Double-Blind, Randomized, Pharmacokinetic and Pharmacodynamic Trial of ID-6556 in Subjects with Acute-on-Chronic Liver Failure Available 3 Available 13/11/2014 Total recruited at site = 1; Extended timeline by sponsor 13/EE/0241 Secukinumab In with moderate to severe active, chronic plaque psoriasis who have failed on TFa antagoists: A clinical Trial EvalUating Treatment Results (SIGATURE) Available 2 Available 09/10/2014 Open Total recruited at site = 3; Timeline extended from the original date in contract 09/10/2014 to 31/12/2014 further to 31/03/ /EM/0414 A Double-blind, Randomised, Placebo-controlled Study to Investigate the Efficacy and Safety of Mepolizumab in the Treatment of Eosinophilic Granulomatosis withpolyangiitis in Subjects Receiving Standard of Care Therapy. Available 2 Available 01/06/2014 Total recruited at site = 7 13/SC/0558 A 52-week, multicenter, randomized, double-blind, placebo-controlled study of subcutaneous secukinumab to demonstrate efficacy as assessed by palmoplantar pustulosis Psoriasis Area and Severity Index (pppasi) at 16 weeks of treatment, compared to placebo, and to assess long-term safety, tolerability, and efficacy in subjects with moderate to severe chronic palmoplantar pustular psoriasis. Available 5 Available 12/12/2014 Total recruited at site = 7 13/EE/0276 A Phase 3B Randomized, Open-Label Multi-Center Trial Assessing Sofosbuvir + Ribavirin for 16 or 24 Weeks and Sofosbuvir + Pegylated Interferon + Ribavirin for 12 Weeks in Subjects with Genotype 2 or 3 Chronic HCV Infection Available 8 Available 31/05/2014 Total recruited at site = 13 13/EM/0348 Safety and Efficacy assessment of Monoprost? (unpreserved latanoprost) incomparison with Lumigan? 0.01 % and Lumigan? 0.03% UD, in with primaryopen angle glaucoma or ocular hypertension, stabilized by Lumigan? 0.01 % withocular surface intolerance. Available 6 Available 30/09/2014 Open Total recruited at site = 9; Extended clinical phase from Sept 2014 to Dec 2015

3 11/H/0140 LUMIOUS: Study to observe the effectiveness and safety of LUCETIS? through individualized patient treatment and associated outcomes" Available 100 Available 02/12/2014 Total recruited at site = /WM/0341 A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When AMG 145 is Used in Combination With Statin Therapy In Patients with Clinically Evident Cardiovascular Disease Available 10 Available 31/03/2015 Open /A Total recruited at site = 8; Study extended by sponsor from 30/11/14 to 31/03/ /SW/0148 An Observational Post-Authorization Safety Study (PASS) of Victrelis? (boceprevir) among Chronic Hepatitis C (CHC) (P08518) Available 8 Available 01/07/2014 Total recruited at site = 10 11/LO/1921 A randomized, two-arm, open-label, multicenter Phase II trial assessing the efficacy and safety of pertuzumab given in combination with trastuzumab plus an aromatase inhibitor in first line with HER2-positive and hormone receptor-positive advanced (metastatic or locally advanced) breast cancer. Available 3 Available 31/10/2014 Total recruited at site = 2 12/LO/1680 An observational study of avastin? (bevacizumab) as first line therapy in with advanced ovarian cancer Available 15 Available 31/03/2016 Open /A Total recruited at site = 10 12/WS/0300 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REG727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome Available 11 Available 01/03/2016 Open Total recruited at site = 14, maximum of 25 as oulined by sponsor in contract 13/LO/0528 An Open-label, Randomized, Controlled, Multicenter Study ExplorIng Two Treatment Strategies of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention Available 6 Available 01/12/2015 Open /A Total recruited at site = 1; Contract extended by sponsor

4 12/E/0361 An observational, non-interventional multi-center, multi-national study with Atypical Hemolytic-Uremic Syndrome (ahus Registry) Available 3 Available 01/06/2017 Open Total recruited at site = 3 13/LO/0549 A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of FG for the Treatment of Anemia in Chronic Kidney Disease Patients not on Dialysis Available 7 Available 30/10/2015 Open /A Total recruited at site = 2; Contract extended by sponsor 13/WA/0080 Observational Study Protocol IM101348ST LOG- TERM EXPERIECE WITH ABATACEPT SC I ROUTIE CLIICAL PRACTICE STUD ASCORE Available 6 Available 31/12/2015 Open /A Total recruited at site = 1 13/LO/0807 A Phase 2a, Randomized, Double-Blind, Placebo- Controlled, Multicenter, Parallel-Group Study of JJ ASH2001 in Syptomatic Adult Subjects with Uncontrolled, Persistent Asthma. Available 3 Available 31/10/2014 Total recruited at site = 7; Study extended by sponsor from 31/10/14 to 11/12/14 13/EM/0251 A multicenter, randomized, double-blind, placebocontrolled phase III study to evaluate the efficacy, safety and tolerability of Serelaxin when added to standard therapy in acute heart failure Available 20 Available 21/12/2015 Open /A Total recruited at site = 3 13/E/0345 LIVE:LIFE older heart failure Initiated on ivabradine in UK - quality of life Available 10 Available 31/03/2015 Open /A Total recruited at site =7; 30/06/2014 in contract but extended to 31/12/2014 and later to 31/03/2015 by sponsor 14/LO/0080 A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor, PCI (Ibrutinib), in Combination with Either Bendamustine and Rituximab (BR) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects with Previously Treated Indolent on-hodgkin Lymphoma (ihl) Available 4 Available 30/06/2015 Open /A Total recruited at site = 2; Extended by sponsor from 01/12/2014 to 30/06/2015

5 14/EE/0035 Multicentre, Randomised, Double-Blind, Placebo Controlled, Phase 3 Trial of Fulvestrant (Faslodex?) With or Without PD (Palbociclib)? Goserelin in Women with Hormone Receptor- Positive, HER2-egative Metastatic Breast Cancer Whose Disease Progressed After Prior Endocrine Therapy Available 2 Available 31/07/2014 total recruited at site n = 1; revised target (5 to 2) and closure date (31/10/14 to 31/07/14) 14/WS/1055 An open-label study of inhaler device attributes investigating critical and overall errors, ease of use, and preference between a number of inhaler devices (ELLIPTA, TURBUHALER, HADIHALER, BREEZHALER, MDI, and DISKUS/ACCUHALER) in adult subjects with Chronic Obstructive Pulmonary Disease (COPD) Available 100 Available 02/03/2015 Open /A Total recruited at site = 12 14/WS/1017 The Impact of Rifaximin-a on the HS Hospital Resource Use Associated with the Management of Patients with Hepatic Encephalopathy: A Retrospective Observational Study (IMPRESS) Available 20 Available 25/11/2014 Total recruited at site = 20 14/WS/1001 A prospective, multicenter, open-label, centrally allocated, active-controlled,phase 2 study to evaluate the efficacy and safety ofmasitinib in combination with gemcitabine versus gemcitabinealone in advanced/metastatic epithelial ovarian cancer insecond line being refractory to first line platinum treatment or inthird line. Available 5 Available 28/02/2016 Open /A Total recruited at site = 1 14/LO/0087 An observational study on clearance on biologics in plaque psoriasis Available 10 Available 29/02/2016 Open /A Total recruited at site = 6

Date Agreed to recruit target number of patients available. Target number of patients. Available 100 Available 02/12/2014

Date Agreed to recruit target number of patients available. Target number of patients. Available 100 Available 02/12/2014 Research Ethics Committee Reference umber ame of Trial Target number of patients available Target number of patients Date Agreed to recruit target number of patients available Date Agreed to recruit target

More information

Perfomance in Delivering (Commercial Trials)

Perfomance in Delivering (Commercial Trials) Perfomance in Delivering (Commercial Trials) REC Ref IRAS ID Name of Trial Target Of? Minimum Of Maximum Of Target Date To Recruit? Total Date Of to recruit target number Recruited At of patients The Target

More information

Min number of patients agreed to be recruited. Max number of patients agreed to be recruited

Min number of patients agreed to be recruited. Max number of patients agreed to be recruited be 12/SC/0139 98125 A PHASE III PROSPECTIVE, TWO-COHORT NON-RANDOMIZED, MULTI- CENTRE, MULTINATIONAL, OPEN LABEL STUDY TO ASSESS THE SAFETY OF ASSISTED- AND SELF-ADMINISTERED SUBCUTANEOUS TRASTUZUMAB AS

More information

Performance in Delivering Q4. Target number of patients

Performance in Delivering Q4. Target number of patients Performance in Delivering Q4 Research Ethics Committee Reference Number Name of Trial Target number of patients Date Agreed to recruit target number of patients Trial Status Target met within the agreed

More information

The Pennine Acute Hospitals NHS Trust Performance in delivering clinical research Reporting period 1 October 2017 to 30 September 2018

The Pennine Acute Hospitals NHS Trust Performance in delivering clinical research Reporting period 1 October 2017 to 30 September 2018 The Pennine Acute Hospitals NHS Trust Performance in delivering clinical research Reporting period 1 October 2017 to 30 September 2018 REC reference IRAS reference Name of trial Target number of? Minimum

More information

Table 2: Salford Royal NHS Foundation Trust: Performance in delivering clinical research: Reporting period 1 January December 2014

Table 2: Salford Royal NHS Foundation Trust: Performance in delivering clinical research: Reporting period 1 January December 2014 Table 2: Salford Royal HS Foundation Trust: Performance in delivering clinical research: Reporting period 1 January 2014 1 December 2014 Research Ethics Committee reference number 1 12/W/0321 2 11/LO/1986

More information

Target date to recruit patients agreed? Target range minimum. Target range maximum. Agreed 1 1 Agreed 01/01/ /01/2016 Recruitment Finished

Target date to recruit patients agreed? Target range minimum. Target range maximum. Agreed 1 1 Agreed 01/01/ /01/2016 Recruitment Finished No REC Reference IRAS No Title Target number of patients agreed? Target range minimum Target range maximum Target date to recruit patients agreed? Planned Recruitment end date No of patients recruited

More information

Performance in Initiating Clinical Research Q4 2015/16

Performance in Initiating Clinical Research Q4 2015/16 Performance in Initiating Clinical Research Q4 2015/16 Research Ethics Committee Reference Number Integrated Research Application System Number Name of Trial Date of Receipt of Valid Research Application

More information

New Product to Market: Trelegy Ellipta Magellan Health, Inc. All rights reserved.

New Product to Market: Trelegy Ellipta Magellan Health, Inc. All rights reserved. Drug Review and The following tables list the Agenda items as well as the that are scheduled to be presented and reviewed at the March 15, 2018 meeting of the Pharmacy and Therapeutics Advisory Committee.

More information

Performance in Initiating Clinical Research

Performance in Initiating Clinical Research Performance in Initiating Clinical Research January 2016 December 2016 NHS Permissions Site approval Research Ethics Committee Reference Number Integrated Research Application System Number Name of Trial

More information

Studies proceeding under pre HRA-Approval system (NHS Permission)

Studies proceeding under pre HRA-Approval system (NHS Permission) 15/NW/0004 162679 Studies proceeding under pre HRA-roval system (NHS Permission) A MULTI-CENTRE RANDOMISED CLINICAL TRIAL OF BIOMARKER-DRIVEN MAINTENANCE TREATMENT FOR FIRST- LINE METASTATIC COLORECTAL

More information

Integrated Research Application System Number. Total Number Of Study Participants Recruited. Research Ethics Committee Reference Number

Integrated Research Application System Number. Total Number Of Study Participants Recruited. Research Ethics Committee Reference Number Research Ethics Committee Reference Number Integrated Research Application System Number Name of Trial Minimum Number Of Patients Agreed Maximum Number Of Patients Agreed Date That The Trial Closed To

More information

Kentucky Department for Medicaid Services Pharmacy and Therapeutics Advisory Committee Recommendations

Kentucky Department for Medicaid Services Pharmacy and Therapeutics Advisory Committee Recommendations Kentucky Department for Medicaid Services Pharmacy and March 15, 2018 The following chart provides a summary of the recommendations that were made by the Pharmacy and Therapeutics (P&T) Advisory Committee

More information

Target date to recruit patients agreed? Target range minimum. Target range maximum

Target date to recruit patients agreed? Target range minimum. Target range maximum No REC Reference IRAS No Title Target number of patients agreed? Target range minimum Target range maximum Target date to recruit patients agreed? Planned Recruitment end date Total no of patients recruited

More information

NIHR Performance Metrics - Initiating Clinical Research. Quarter 1 ( )

NIHR Performance Metrics - Initiating Clinical Research. Quarter 1 ( ) NIHR Performance Metrics - Initiating Clinical Research Quarter 1 (2014-2015) Research Ethics Committee Reference Number Name of Trial Date of Receipt of Valid Research Application Date of First Patient

More information

The Pennine Acute Hospitals NHS Trust Performance in initiating clinical research Reporting period 1 October 2017 to 30 September 2018

The Pennine Acute Hospitals NHS Trust Performance in initiating clinical research Reporting period 1 October 2017 to 30 September 2018 The Pennine Acute Hospitals NHS Trust Performance in initiating clinical research Reporting period 1 October 2017 to 30 September 2018 REC reference IRAS reference Name of trial First patient recruited?

More information

Table 1: Salford Royal NHS Foundation Trust: Performance in initiating clinical research: Reporting period 1 October September 2013

Table 1: Salford Royal NHS Foundation Trust: Performance in initiating clinical research: Reporting period 1 October September 2013 Table 1: Salford Royal NHS Foundation Trust: Performance in initiating clinical research: Reporting period 1 October 2012-30 September 2013 Research Ethics Committee reference number Name of Trial 1 12/NW/0321

More information

Performance in Initiating Clinical Research Q2 2016/17

Performance in Initiating Clinical Research Q2 2016/17 Performance in Initiating Clinical Research Q2 2016/17 Research Ethics Committee Reference Number Integrated Research Application System Number Name of Trial Date of Receipt of Valid Research Application

More information

Table 1: Salford Royal NHS Foundation Trust: Performance in initiating clinical research: Reporting period 1 April March 2014

Table 1: Salford Royal NHS Foundation Trust: Performance in initiating clinical research: Reporting period 1 April March 2014 Table 1: Salford Royal NHS Foundation Trust: Performance in initiating clinical research: Reporting period 1 April 2013-31 March 2014 Research Ethics Committee Name of Trial reference number 1 08/H0906/140

More information

NIHR Performance Metrics - Initiating Clinical Research. Quarter 2 ( )

NIHR Performance Metrics - Initiating Clinical Research. Quarter 2 ( ) NIHR Performance Metrics - Initiating Clinical Research Quarter 2 (2014-2015) Research Ethics Committee Reference Number Name of Trial Date of Receipt of Valid Research Application Date of First Patient

More information

PERFORMANCE IN DELIVERING CLINICAL RESEARCH (Q1, 2016/17)

PERFORMANCE IN DELIVERING CLINICAL RESEARCH (Q1, 2016/17) PERFORMANCE IN DELIVERING CLINICAL RESEARCH (Q1, 2016/17) Research Ethics Committee Reference Name of Trial Target Of Patients? Minimum Of Patients (Enter Same In Both If Only One ) Maximum Of Patients

More information

NIHR Performance Metrics - Initiating Clinical Research. Quarter 4 ( )

NIHR Performance Metrics - Initiating Clinical Research. Quarter 4 ( ) NIHR Performance Metrics - Initiating Clinical Research Quarter 4 (2013-2014) Research Ethics Committee Reference Number Name of Trial Date of Receipt of Valid Research Application Date of First Patient

More information

NICE TECHNOLOGY APPRAISAL MEDICINES REPORT 2017

NICE TECHNOLOGY APPRAISAL MEDICINES REPORT 2017 NICE TECHNOLOGY PPRISL MEDICINES REPORT St George s Healthcare NHS Trust key for medicine-related NICE Technology ppraisals. has been approved by the Drugs and Therapeutics Committee as recommended within

More information

Target date to recruit patients agreed? Target range. maximum. minimum. Date. 5 Agreed 26/01/ /11/2015 Recruitment Finished.

Target date to recruit patients agreed? Target range. maximum. minimum. Date. 5 Agreed 26/01/ /11/2015 Recruitment Finished. No REC Reference IRAS No Title Target number of agreed? Target range minimum Target range maximum Target date to recruit agreed? Planned Recruitment end date Total no of recruited at the agreed target

More information

Table 1 Salford Royal NHS Foundation Trust: Performance in initiating clinical research (HRA Approval) Reporting period 1 April March 2017

Table 1 Salford Royal NHS Foundation Trust: Performance in initiating clinical research (HRA Approval) Reporting period 1 April March 2017 Table 1 Salford Royal NHS Foundation Trust: Performance in initiating clinical research (HRA Approval) Reporting period 1 April 2016 31 March 2017 REC reference IRAS number Study title 16/NW/0428 207062

More information

Performance in Initiating and Delivering Clinical Research

Performance in Initiating and Delivering Clinical Research Performance in Initiating and Delivering Clinical Research As a global leading centre for research in Eyes and Vision, it is a key priority to offer as many as possible the opportunity to get involved

More information

Table 1: Salford Royal NHS Foundation Trust: Performance in initiating clinical research: Reporting period 1 July June 2013

Table 1: Salford Royal NHS Foundation Trust: Performance in initiating clinical research: Reporting period 1 July June 2013 Table 1: Salford Royal NHS Foundation Trust: Performance in initiating clinical research: Reporting period 1 July 2012-30 June 2013 Name of trial Note, some study titles are shortened 1 Long-Term Study

More information

New Developments in Cancer Treatment. Dulcinea Quintana, MD

New Developments in Cancer Treatment. Dulcinea Quintana, MD New Developments in Cancer Treatment Dulcinea Quintana, MD Mortality Rates Goals of treatment 1 Cure Goal of treatment 2 Prolong life Goals of treatment 3 Improve Quality of Life Goals of treatment 4

More information

Clinical Research Institute HUCH Sponsored, fully signed Clinical Trial Agreements (except grants)

Clinical Research Institute HUCH Sponsored, fully signed Clinical Trial Agreements (except grants) , fully signed Clinical Trial Agreements (except grants) Sponsor Full name of the Hospital clinic where the is details of the January x x January x NightstaRx Ltd A Randomised, Open Label, Outcomes-Assessor

More information

Summary of Strategic Competitive Analysis and Publication Planning

Summary of Strategic Competitive Analysis and Publication Planning Summary of Strategic Competitive Analysis and Publication Planning Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Briefing

More information

Chronic Lymphocytic Leukemia Update. Learning Objectives

Chronic Lymphocytic Leukemia Update. Learning Objectives Chronic Lymphocytic Leukemia Update Ashley Morris Engemann, PharmD, BCOP, CPP Clinical Associate Adult Stem Cell Transplant Program Duke University Medical Center August 8, 2015 Learning Objectives Recommend

More information

CENTER FOR CLINICAL TRIALS St. Luke s Medical Center. Ongoing Clinical Trials CANCER INSTITUTE (36)

CENTER FOR CLINICAL TRIALS St. Luke s Medical Center. Ongoing Clinical Trials CANCER INSTITUTE (36) CENTER FOR CLINICAL TRIALS St. Luke s Medical Center Ongoing Clinical Trials CANCER INSTITUTE (36) BLOOD TITLE : A Randomized, Two By Two Arm, Multicenter, Open-Label Phase III Study Of BMS-354825 Administered

More information

CLINICAL TRIALS ACC. Jul 2016

CLINICAL TRIALS ACC. Jul 2016 CLINICAL TRIALS ACC Jul 2016 Glioblastoma BRAIN A071102 A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

More information

Performance in Initiating and Delivering Clinical Research

Performance in Initiating and Delivering Clinical Research Performance in Initiating and Delivering Clinical Research As a global leading centre for research in Eyes and Vision, it is a key priority to offer as many patients as possible the opportunity to get

More information

NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Fall Conference Call 23 November 2009 SUMMARY REPORT

NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Fall Conference Call 23 November 2009 SUMMARY REPORT NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Fall Conference Call 23 November 2009 SUMMARY REPORT The NCIC CTG DSMC reviewed the following trials with respect to safety, trial conduct, including

More information

OPEN TRIALS Accruals counted until 30-April Current Accrual

OPEN TRIALS Accruals counted until 30-April Current Accrual Disease group Breast OPEN TRIALS Trial Title Accrual Target IBCSG 48-14 POSITIVE IBCSG 50-14 OLYMPIA IBCSG 52-15 PALLAS SAKK 21/12 A study evaluating the pregnancy outcomes and safety of interrupting endocrine

More information

Outcomes of patients with CLL after discontinuing idelalisib

Outcomes of patients with CLL after discontinuing idelalisib Outcomes of patients with CLL after discontinuing idelalisib Jacqueline C. Barrientos, Manmeen Kaur, Alexis Mark, Jaewon Chung, Nancy Driscoll, Alison Bender, Kanti R. Rai ASH Annual Meeting Abstracts

More information

Barnes, Maisha. Habib, Adil. Kedia, Prashant

Barnes, Maisha. Habib, Adil. Kedia, Prashant Study Title PI Area of Discipline A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-

More information

WASHINGTON. Spokane Cheney. Olympia. Tri-Cities. Walla Walla. Portland North Central Oregon City OREGON. Mt. Vernon. Port Angeles

WASHINGTON. Spokane Cheney. Olympia. Tri-Cities. Walla Walla. Portland North Central Oregon City OREGON. Mt. Vernon. Port Angeles 2 3 Mt. Vernon Port Angeles Bremerton Tacoma 5 5 Olympia Everett Edmonds Seattle 90 WASHINGTON 90 Spokane Cheney Pullman Longview 82 Tri-Cities Portland North Central Oregon City 5 84 OREGON Walla Walla

More information

Performance in Delivering - Q2 2015/2016. Date Agreed to recruit target number of patients. Trial Status. 2 01/12/2015 Open N/A

Performance in Delivering - Q2 2015/2016. Date Agreed to recruit target number of patients. Trial Status. 2 01/12/2015 Open N/A 12/SC/0394 11/SC/0272 12/LO/0482 A Randomized, Open Label Study of Ofatumumab and Bendamustine Combination Therapy Compared with Bendamustine Monotherapy in Indolent Bcell onhodgkin?s Lymphoma Unresponsive

More information

Trial of Letrozole + Palbociclib/Placebo in Metastatic Endometrial Cancer

Trial of Letrozole + Palbociclib/Placebo in Metastatic Endometrial Cancer Find Studies About Studies Submit Studies Resources About Site Trial of Letrozole + Palbociclib/Placebo in Metastatic Endometrial Cancer The safety and scientific validity of this study is the responsibility

More information

Summary of late stage clinical trials. As of Jul. 22, 2016

Summary of late stage clinical trials. As of Jul. 22, 2016 Summary of late stage clinical trials As of Jul. 22, 2016 List of abbreviations AE BID DLT GFR iv MTD ORR OS PD PFS PK po PPK Q2W Q3W Q4W QD QW sc TID Adverse Events Twice daily Dose Limiting Toxicity

More information

European Medicines Agency decision

European Medicines Agency decision EMA/151867/2018 European Medicines Agency decision P/0107/2018 of 11 April 2018 on the acceptance of a modification of an agreed paediatric investigation plan for benralizumab (Fasenra), (EMEA-001214-PIP01-11-M07)

More information

Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL

Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL New Evidence reports on presentations given at ASH 2009 Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL From ASH 2009: Non-Hodgkin

More information

National Horizon Scanning Centre. Temsirolimus (Torisel) for mantle cell lymphoma - relapsed and/or refractory. January 2008

National Horizon Scanning Centre. Temsirolimus (Torisel) for mantle cell lymphoma - relapsed and/or refractory. January 2008 Temsirolimus (Torisel) for mantle cell lymphoma - relapsed and/or refractory January 2008 This technology summary is based on information available at the time of research and a limited literature search.

More information

Performance in Initiating and Delivering Clinical Research

Performance in Initiating and Delivering Clinical Research Performance in Initiating and Delivering Clinical Research As a global leading centre for research in Eyes and Vision, it is a key priority to offer as many patients as possible the opportunity to get

More information

NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT

NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT The NCIC CTG DSMC reviewed the following trials with respect to safety, trial conduct, including accrual, and

More information

University Hospitals of Leicester NHS Trust Research & Innovation Directorate Performance in Delivering Research 01/04/2015 to 31/03/2016

University Hospitals of Leicester NHS Trust Research & Innovation Directorate Performance in Delivering Research 01/04/2015 to 31/03/2016 University Hospitals of Leicester NHS Trust Research & Innovation Directorate Performance in Delivering Research 01/04/2015 to 31/03/2016 REC Date 10/H0808/109 58307 EXCEL Clinical Trial 1.0 8th June 2010

More information

Inflammatory bowel disease (IBD) Overview of the Paediatric investigation plans. Presented by: Richard Veselý. An agency of the European Union

Inflammatory bowel disease (IBD) Overview of the Paediatric investigation plans. Presented by: Richard Veselý. An agency of the European Union Inflammatory bowel disease (IBD) Overview of the Paediatric investigation plans Presented by: Richard Veselý An agency of the European Union Adalimumab - Crohn s disease Indication: Treatment of severe,

More information

Performance in Initiating and Delivering Clinical Research Why are we doing this?

Performance in Initiating and Delivering Clinical Research Why are we doing this? Performance in Initiating and Delivering Clinical Research Why are we doing this? Through the NIHR (National Institute for Health Research) the Government wishes to see a dramatic and sustained improvement

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, for early-stage triple-negative breast cancer, 740 742 in older early-stage breast cancer patients, 790 795 anti-her2-directed

More information

Open Trials as of end of March 2016

Open Trials as of end of March 2016 EORTC 10085 PRO EORTC 10085 prospective part, Clinical and biological characterization of Male Breast Cancer: an international EORTC, BIG and NABCG inter study 30 30-Jun-2016 estelle.cassoly@sakk.ch IBCSG

More information

NIHR Performance Metrics - Initiating Clinical Research. Quarter 3 ( )

NIHR Performance Metrics - Initiating Clinical Research. Quarter 3 ( ) NIHR Performance Metrics - Initiating Clinical Research Quarter 3 (2014-2015) Research Ethics Committee Reference Number 13/LO/0291 Name of Trial Insight Insulin Pump EU Study: A European Multicenter Study

More information

RITUXAN (rituximab and hyaluronidase human)

RITUXAN (rituximab and hyaluronidase human) Drug Prior Authorization Guideline RITUXIMAB products J9310 RITUXAN (rituximab and hyaluronidase human) PA9847 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria

More information

HMO: Medical (provider setting); Rx (out patient) PPO/CDHP: Rx

HMO: Medical (provider setting); Rx (out patient) PPO/CDHP: Rx BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Epogen, Procrit (epoetin alfa, injection) Commercial HMO/PPO/CDHP

More information

HEALTH MATTERS, INC. SUMMARY OF PROJECTS AND KEY ACCOMPLISHMENTS TO 2016

HEALTH MATTERS, INC. SUMMARY OF PROJECTS AND KEY ACCOMPLISHMENTS TO 2016 Selected 2016 Highlights Epidemiologic research on chronic kidney disease and fistula patency, solid and hematologic malignancies Health economics and outcomes research on beta3-agonist treatment for overactive

More information

Date of NHS Permission. Date of First Patient Recruited. Date Site Invited

Date of NHS Permission. Date of First Patient Recruited. Date Site Invited Reference of Receipt of of NHS of First 14/WA/1075 150715 NHS HeadPoST Version 2.1 23/11/2015 05/01/2016 11/01/2016 N/A 12/YH/0452 106985 NHS INCA 10/12/2015 15/01/2016 17/03/2016 N/A Excess Treatment

More information

SYNOPSIS. Clinical Study Report IM Double-blind Period

SYNOPSIS. Clinical Study Report IM Double-blind Period Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Abatacept () Name of Active Ingredient: Abatacept () Individual Study Table Referring to the Dossier SYNOPSIS (For National Authority

More information

8th Emirates Cardiac Society Congress in collaboration with ACC Middle East Conference Dubai: October Acute Coronary Syndromes

8th Emirates Cardiac Society Congress in collaboration with ACC Middle East Conference Dubai: October Acute Coronary Syndromes 8th Emirates Cardiac Society Congress in collaboration with ACC Middle East Conference 2017 Dubai: 19-21 October 2017 Acute Coronary Syndromes Antonio Colombo Centro Cuore Columbus and S. Raffaele Scientific

More information

Avastin. Avastin (bevacizumab) Description

Avastin. Avastin (bevacizumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.04 Subject: Avastin Page: 1 of 9 Last Review Date: September 20, 2018 Avastin Description Avastin

More information

List of Recombinant DNA based Drugs Approved in the Country (Form-45) 1st Jan st Dec 2013

List of Recombinant DNA based Drugs Approved in the Country (Form-45) 1st Jan st Dec 2013 S.No. 1 Name of the firm Ferring Date of Approval 4-Apr-10 License No. Import-450/10 2 G.C.Chemie 23-Jun-10 IMP-572/10 3 R.K. Medicare 9-Sep-10 IMP-783/10 4 5 List of Recombinant DNA based Drugs Approved

More information

Performance Against Dirst Patient Visit Benchmark

Performance Against Dirst Patient Visit Benchmark 11/LO/1873 Stent Oesophageal Varices (SOV) Study 09/07/2012 05/02/2013 and Trust 11/SC/0410 VIT 09 10 02/07/2012 Reasons for delay rest with the Sponsor 12/SW/0177 Electrical muscle stimulation in mechanical

More information

Committee Approval Date: May 9, 2014 Next Review Date: May 2015

Committee Approval Date: May 9, 2014 Next Review Date: May 2015 Medication Policy Manual Policy No: dru180 Topic: Promacta, eltrombopag Date of Origin: May 8, 2009 Committee Approval Date: May 9, 2014 Next Review Date: May 2015 Effective Date: June 1, 2014 IMPTANT

More information

eltrombopag (Promacta )

eltrombopag (Promacta ) Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided

More information

Open and Pending Trials Listing For Arizona Oncology Associates P.C. HOPE Division/ Tucson, Arizona

Open and Pending Trials Listing For Arizona Oncology Associates P.C. HOPE Division/ Tucson, Arizona Open and Pending Trials Listing For Arizona Oncology Associates P.C. HOPE Division/ Tucson, Arizona Solid Tumor: USON 15180 / A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab

More information

Rituximab and Combination Chemotherapy in Treating Patients With Non- Hodgkin's Lymphoma

Rituximab and Combination Chemotherapy in Treating Patients With Non- Hodgkin's Lymphoma Page 1 of 5 Home Search Study Topics Glossary Search Full Text View Tabular View No Study Results Posted Related Studies Rituximab and Combination Chemotherapy in Treating Patients With Non- Hodgkin's

More information

Palliative Low Grade Lymphoma & Hairy Cell Leukemia Regimens. Low Grade Lymphoma

Palliative Low Grade Lymphoma & Hairy Cell Leukemia Regimens. Low Grade Lymphoma Palliative Low Grade Lymphoma & Hairy Cell Leukemia Regimens The following table lists the evidence-informed regimens (both IV and non-iv) for low grade lymphoma and Hairy Cell leukemia used in the palliative

More information

European Medicines Agency decision

European Medicines Agency decision EMA/501681/2016 European Medicines Agency decision P/0213/2016 of 12 August 2016 on the acceptance of a modification of an agreed paediatric investigation plan for benralizumab (EMEA- 001214-PIP01-11-M05)

More information

HRA Approval Date. confirmed by sponsor 07/04/ /04/ /04/ /04/ /04/ /04/ /05/2016

HRA Approval Date. confirmed by sponsor 07/04/ /04/ /04/ /04/ /04/ /04/ /05/2016 Reference Reason for delay in recruiting first 1 15/NE/0144 179243 AN OPEN-LABEL EXTENSION AND SAFETY MONITORING STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN S DISEASE PREVIOUSLY ENROLLED

More information

London Cancer New Drugs Group. February London Cancer New Drugs Group (LCNDG) Work Plan for the London Cancer Drugs Fund list.

London Cancer New Drugs Group. February London Cancer New Drugs Group (LCNDG) Work Plan for the London Cancer Drugs Fund list. February 2013 London Cancer New s Group (LCNDG) Work Plan for the London Cancer s Fund London Cancer s Fund List This Cancer s Fund (CDF) list of medicines and s is in two parts. 1. The standard list of

More information

South London and Maudsley NHS Foundation Trust: FY1819 Q2 Performance in Initiating

South London and Maudsley NHS Foundation Trust: FY1819 Q2 Performance in Initiating of First 17/YH/0195 228739 17/YH/0196 228435 17/LO/0987 215947 17/LO/1314 224111 17/WM/0441 224759 17/LO/1867 229005 A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity

More information

A randomised controlled clinical trial in type 2 diabetes comparing semaglutide to placebo and liraglutide

A randomised controlled clinical trial in type 2 diabetes comparing semaglutide to placebo and liraglutide A randomised controlled clinical trial in type 2 diabetes comparing semaglutide to placebo and liraglutide This trial was conducted in Europe,Asia and Africa. Study participants were randomised evenly

More information

Trial record 1 of 6 for: mcl 3002 Previous Study Return to List Next Study

Trial record 1 of 6 for: mcl 3002 Previous Study Return to List Next Study A service of the U.S. National Institutes of Health Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials Trial record

More information

National Horizon Scanning Centre. Aflibercept (VEGF Trap) for advanced chemo-refractory epithelial ovarian cancer. December 2007

National Horizon Scanning Centre. Aflibercept (VEGF Trap) for advanced chemo-refractory epithelial ovarian cancer. December 2007 Aflibercept (VEGF Trap) for advanced chemo-refractory epithelial ovarian cancer December 2007 This technology summary is based on information available at the time of research and a limited literature

More information

MANTLE CELL LYMPHOMA

MANTLE CELL LYMPHOMA MANTLE CELL LYMPHOMA CLINICAL CASE PRESENTATION Martin Dreyling Medizinische Klinik III LMU München Munich, Germany esmo.org Multicenter Evaluation of MCL Annency Criteria fulfilled event free interval

More information

Notification to Implement Issued by pcodr: December 14, 2012

Notification to Implement Issued by pcodr: December 14, 2012 PROVINCIAL FUNDING SUMMARY Bendamustine hydrochloride (Treanda) for indolent Non-Hodgkin Lymphoma and Mantle Cell Lymphoma (first-line and relapsed/refractory) perc Recommendation: Recommends For further

More information

Pharmacy Management Drug Policy

Pharmacy Management Drug Policy SUBJECT: : Nucala (mepolizumab), Cinqair (reslizumab), & Fasenra (benralizumab) POLICY NUMBER: Pharmacy-62 EFFECTIVE DATE: 12/15 LAST REVIEW DATE: 3/5/2018 If the member s subscriber contract excludes

More information

12 th Annual Hematology & Breast Cancer Update Update in Lymphoma

12 th Annual Hematology & Breast Cancer Update Update in Lymphoma 12 th Annual Hematology & Breast Cancer Update Update in Lymphoma Craig Okada, MD, PhD Assistant Professor, Hematology January 14, 2010 Governors Hotel, Portland Oregon Initial Treatment of Indolent Lymphoma

More information

National Horizon Scanning Centre. Sunitinib (Sutent) for advanced and/or metastatic breast cancer. December 2007

National Horizon Scanning Centre. Sunitinib (Sutent) for advanced and/or metastatic breast cancer. December 2007 Sunitinib (Sutent) for advanced and/or metastatic breast cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not

More information

Contents Please refer to Medical Policy I-40 Pertuzumab (Perjeta) for additional information.

Contents Please refer to Medical Policy I-40 Pertuzumab (Perjeta) for additional information. May 2018 In This Issue Coverage Guidelines Revised for Azacitidine (Vidaza)... 3 Coverage Guidelines Revised for Fulvestrant (Faslodex)... 4 Place of Service Revised for Total Hip and Total Knee Arthroplasty...

More information

NBPDP Formulary Update

NBPDP Formulary Update Bulletin #878 December 19, 2013 NBPDP Formulary Update This update to the New Brunswick Prescription Drug Program (NBPDP) Formulary is effective December 19, 2013. Included in this bulletin: Regular Benefit

More information

Ribavirin (Medicare Prior Authorization)

Ribavirin (Medicare Prior Authorization) Prior Authorization Form ARKANSAS BLUE CROSS AND BLUE SHIELD Medi-Pak Rx (PDP), Medi-Pak Advantage (PFFS), and Medi-Pak Advantage PPO Ribavirin (Medicare Prior Authorization) This fax machine is located

More information

The Clinical Research E-News

The Clinical Research E-News Volume 3: ISSUE 5: March 23, 2011 The Clinical Research E-News Now Open: CALGB 90802, Randomized Phase III trial comparing everolimus plus placebo versus everolimus plus bevacizumab for advanced renal

More information

Highlights in chronic lymphocytic leukemia

Highlights in chronic lymphocytic leukemia Congress Highlights CLL Highlights in chronic lymphocytic leukemia A. Janssens, MD, PhD 1 As new data on indolent non-hodgkin lymphoma (inhl) were not that compelling, only highlights on chronic lymphocytic

More information

Clinical Research Institute HUCH Sponsored, fully signed Clinical Trial Agreements (except grants)

Clinical Research Institute HUCH Sponsored, fully signed Clinical Trial Agreements (except grants) 1. 2. The is Sponsor Full name of the Hospital clinic where the is details of the January January NightstaR Ltd A Randomised, Open Label, Outcomes-Assessor Masked, Prospective, Parallel Controlled Group,

More information

Clinical Policy: Idelalisib (Zydelig) Reference Number: ERX.SPA.269 Effective Date:

Clinical Policy: Idelalisib (Zydelig) Reference Number: ERX.SPA.269 Effective Date: Clinical Policy: (Zydelig) Reference Number: ERX.SPA.269 Effective Date: 12.01.18 Last Review Date: 11.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

Avastin (bevacizumab)

Avastin (bevacizumab) Avastin (bevacizumab) Policy Number: 5.02.502 Last Review: 04/2018 Origination: 03/2017 Next Review: 04/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Avastin

More information

Summary of late-stage clinical trials. As of Dec. 31, 2017

Summary of late-stage clinical trials. As of Dec. 31, 2017 Summary of late-stage clinical trials As of Dec. 31, 2017 The document contains information available on the date indicated in its cover page. The public information of clinicaltrials.gov is continuously

More information

Directorate General of Health Services Office of Drugs Controller General (India) (Biological Division)

Directorate General of Health Services Office of Drugs Controller General (India) (Biological Division) Directorate General of Health Services Office of Drugs Controller General (India) (Biological Division) List of r-dna drug products approved in the country (Form 45 and 45A) from 1 st Jan 2015 to 30 th

More information

Date Site Confirmed By Sponsor. Non- Confirmation Status. HRA Approval Date. Date Site Confirmed

Date Site Confirmed By Sponsor. Non- Confirmation Status. HRA Approval Date. Date Site Confirmed Research Ethics Committee Reference Number Integrated Research Application System Number Submission Type Name of Trial First Patient Recruited? Date of First Patient Recruited Invited Selected Approval

More information

Avastin Sample Coding

Avastin Sample Coding First- and Second-line Metastatic Colorectal Cancer C18.0 Malignant neoplasm of the cecum C18.1 Malignant neoplasm of appendix C18.2-C18.9 C19 C20 C21.8 Malignant neoplasm of the colon, various sites Malignant

More information

Chemotherapy-induced HBV reactivation in cancer patients

Chemotherapy-induced HBV reactivation in cancer patients Chemotherapy-induced HBV reactivation in cancer patients On behalf of Taiwan Cooperative Oncology Group (TCOG) HBV reactivation in lymphoma patients: What we have known HBV reactivation and hepatitis flares

More information

SYNOPSIS. Issue Date: 25 Oct 2011

SYNOPSIS. Issue Date: 25 Oct 2011 SYNOPSIS Issue Date: 25 Oct 2011 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Janssen Research & Development STELARA Ustekinumab Protocol No.: Title of Study: Study Name:

More information

Proposing Trastuzumab as an Essential Medicine to Treat Cancer: Insight on Methodologies, Processes and Outcomes. Lorenzo Moja

Proposing Trastuzumab as an Essential Medicine to Treat Cancer: Insight on Methodologies, Processes and Outcomes. Lorenzo Moja Proposing Trastuzumab as an Essential Medicine to Treat Cancer: Insight on Methodologies, Processes and Outcomes Lorenzo Moja Essential Medicines List Secretariat Essential Medicines and Health Products

More information

ALIENOR GINECO-OV222/ENGOT-OV7

ALIENOR GINECO-OV222/ENGOT-OV7 GCIG RARE TUMOUR COMMITTEE Closed Trial status update ISABELLE RAY-COQUARD ALIENOR GINECO-OV222/ENGOT-OV7 Trial setting: Sex chord-stromal ovarian tumors Study Design: Randomized, open label, phase II

More information

Pharmacology Updates in Breast Cancer Chris Vaklavas, M.D.

Pharmacology Updates in Breast Cancer Chris Vaklavas, M.D. Pharmacology Updates in Breast Cancer Chris Vaklavas, M.D. Assistant Professor Department of Medicine, Division of Hematology/Oncology University of Alabama at Birmingham NP2540M 1802 6th Avenue South

More information

Avastin. Avastin (bevacizumab) Description

Avastin. Avastin (bevacizumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.04 Subject: Avastin Page: 1 of 9 Last Review Date: September 15, 2017 Avastin Description Avastin

More information

Patient safety in the Eluvia DES and Ranger DCB programmes

Patient safety in the Eluvia DES and Ranger DCB programmes Patient safety in the Eluvia DES and Ranger DCB programmes William A. Gray, MD Lankenau Heart Institute, Wynnewood, PA, USA Jan 22, 2019 Room 1 - Main Arena Disclosure Speaker name: William Gray I have

More information

ENHT Performance in Delivering - Q3 2015/16. Date Agreed to recruit target. Date Agreed to recruit target. number of. patients available.

ENHT Performance in Delivering - Q3 2015/16. Date Agreed to recruit target. Date Agreed to recruit target. number of. patients available. EHT Performance in Delivering - Q3 2015/16 umber ame 12/SC/0394 A Randomized, Open Label Study Ofatumumab and Bendamustine Combination Therapy Compared with Bendamustine Monorapy in Indolent Bcell onhodgkin's

More information